Pierantonio Menna

6.0k total citations · 1 hit paper
65 papers, 4.8k citations indexed

About

Pierantonio Menna is a scholar working on Cardiology and Cardiovascular Medicine, Oncology and Biophysics. According to data from OpenAlex, Pierantonio Menna has authored 65 papers receiving a total of 4.8k indexed citations (citations by other indexed papers that have themselves been cited), including 47 papers in Cardiology and Cardiovascular Medicine, 32 papers in Oncology and 18 papers in Biophysics. Recurrent topics in Pierantonio Menna's work include Chemotherapy-induced cardiotoxicity and mitigation (45 papers), Cancer Treatment and Pharmacology (25 papers) and Electron Spin Resonance Studies (18 papers). Pierantonio Menna is often cited by papers focused on Chemotherapy-induced cardiotoxicity and mitigation (45 papers), Cancer Treatment and Pharmacology (25 papers) and Electron Spin Resonance Studies (18 papers). Pierantonio Menna collaborates with scholars based in Italy, United States and Malaysia. Pierantonio Menna's co-authors include Giorgio Minotti, Emanuela Salvatorelli, Gaetano Cairo, Luca Gianni, Elvio Covino, Massimo Chello, Antonio M. Calafiore, Odalys Gonzalez Paz, Raffaella Ronchi and Stefania Recalcati and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Oncology and Pharmacological Reviews.

In The Last Decade

Pierantonio Menna

63 papers receiving 4.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Anthracyclines: Molecular Advances and Pharmacologic Developments in Antitumor Activity and Cardiotoxicity

2004 3.0k citations Giorgio Minotti, Pierantonio Menna et al. Pharmacological Reviews profile →

Peers

Countries citing papers authored by Pierantonio Menna

Since Specialization

Citations

This map shows the geographic impact of Pierantonio Menna's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Pierantonio Menna with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Pierantonio Menna more than expected).

Fields of papers citing papers by Pierantonio Menna

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Pierantonio Menna. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Pierantonio Menna. The network helps show where Pierantonio Menna may publish in the future.

Co-authorship network of co-authors of Pierantonio Menna

This figure shows the co-authorship network connecting the top 25 collaborators of Pierantonio Menna. A scholar is included among the top collaborators of Pierantonio Menna based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Pierantonio Menna. Pierantonio Menna is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Fixed-duration therapy of chronic lymphocytic leukemia with venetoclax and Bruton tyrosine kinase inhibitors: an insight into differences between ibrutinib and acalabrutinib 2025 ·Leukemia ·Alessandra Tedeschi, Anna Maria Frustaci, Pierantonio Menna, Giorgio Minotti	0
2	Anthracyclines, Diastolic Dysfunction and the road to Heart Failure in Cancer survivors: An untold story 2024 ·Progress in Cardiovascular Diseases ·Massimiliano Camilli, (unknown), Emanuela Salvatorelli, Pierantonio Menna, Giorgio Minotti	5
3	Quantitative Analysis of Cenobamate and Concomitant Anti-Seizure Medications in Human Plasma via Ultra-High Performance Liquid Chromatography–Tandem Mass Spectrometry 2024 ·Molecules ·(unknown), (unknown), (unknown), Viviana Izzo, Giovanni Assenza, Pierantonio Menna, Ugo de Grazia, (unknown)	4
4	New Targeted Drugs for Acute Myeloid Leukemia and Antifungals: Pharmacokinetic Challenges and Opportunities 2023 ·Chemotherapy ·Emanuela Salvatorelli, Giorgio Minotti, Pierantonio Menna	2
5	Posaconazole and midostaurin in patients with FLT3‐mutated acute myeloid leukemia: Pharmacokinetic interactions and clinical facts in a real life study 2023 ·Clinical and Translational Science ·Pierantonio Menna, Francesco Marchesi, Chiara Cattaneo, Anna Candoni, Mario Delia, Gianpaolo Nadali, (unknown), (unknown), Salvatore Perrone, Luisa Verga, Daniele Armiento, Maria Ilaria Del Principe, Nicola Fracchiolla, Emanuela Salvatorelli, (unknown), Irene Terrenato, Alessandro Busca, Giorgio Minotti, Livio Pagano	3
6	Development and Validation of a UHPLC–MS/MS-Based Method to Quantify Cenobamate in Human Plasma Samples 2022 ·Molecules ·(unknown), (unknown), Francesca Felicia Operto, Giangennaro Coppola, Ugo de Grazia, Pierantonio Menna, Amelia Filippelli, Fabrizio Dal Piaz, Viviana Izzo	10
7	Infectious complications of targeted drugs and biotherapies in acute leukemia. Clinical practice guidelines by the European Conference on Infections in Leukemia (ECIL), a joint venture of the European Group for Blood and Marrow Transplantation (EBMT), the European Organization for Research and Treatment of Cancer (EORTC), the International Immunocompromised Host Society (ICHS) and the European Leukemia Net (ELN) 2022 ·Leukemia ·Georg Maschmeyer, Lars Bullinger, Carolina García‐Vidal, Raoul Herbrecht, Johan Maertens, Pierantonio Menna, Livio Pagano, Anne Thiebaut‐Bertrand, Thierry Calandra	34
8	Ibrutinib and Bruton’s Tyrosine Kinase Inhibitors in Chronic Lymphocytic Leukemia: Focus on Atrial Fibrillation and Ventricular Tachyarrhythmias/Sudden Cardiac Death 2022 ·Chemotherapy ·Giuseppe Boriani, Pierantonio Menna, (unknown), Giorgio Minotti, Marco Vitolo	16
9	Choosing Antifungals for the Midostaurin-Treated Patient: Does CYP3A4 Outweigh Recommendations? A Brief Insight from Real Life 2021 ·Chemotherapy ·Pierantonio Menna, Emanuela Salvatorelli, Maria Ilaria Del Principe, Salvatore Perrone, Livio Pagano, Francesco Marchesi, Giorgio Minotti	9
10	Further Analytical, Pharmacokinetic, and Clinical Observations on Low-Dose Ponatinib in Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia 2020 ·Chemotherapy ·Pierantonio Menna, Ugo de Grazia, Francesco Marchesi, Giorgio Minotti, Emanuela Salvatorelli	2
11	Safety and tolerability of a novel oral nutritional supplement in healthy volunteers 2020 ·Clinical Nutrition ·(unknown), Pierantonio Menna, Giorgio Minotti, Silvia Angeletti, Alessandro Comandini, (unknown), Elisa Quarchioni, (unknown), Enrica Salvatori, (unknown), Sara Emerenziani, Michele Cicala, Maurizio Muscaritoli	6
12	Efficacy and safety of low dose ponatinib in a case of Ph‐positive acute lymphoblastic leukaemia 2019 ·British Journal of Haematology ·Francesco Marchesi, Emanuela Salvatorelli, Daniela Renzi, Andrea Mengarelli, Giorgio Minotti, Pierantonio Menna	6
13	Early Diastolic Dysfunction after Cancer Chemotherapy: Primary Endpoint Results of a Multicenter Cardio-Oncology Study 2018 ·Chemotherapy ·(unknown), Pierantonio Menna, Ombretta Annibali, Grazia Armento, (unknown), Elisabetta Cerchiara, Carlo Greco, Francesco Marchesi, Paolo Spallarossa, (unknown), Giorgio Reggiardo, Giorgio Minotti, (unknown)	23
14	Isavuconazole: Case Report and Pharmacokinetic Considerations 2018 ·Chemotherapy ·Francesco Marchesi, Corrado Girmenia, Bianca Maria Goffredo, Emanuela Salvatorelli, Atelda Romano, Andrea Mengarelli, Giorgio Minotti, Pierantonio Menna	7
15	Primary Prevention Strategies for Anthracycline Cardiotoxicity: A Brief Overview 2017 ·Chemotherapy ·Pierantonio Menna, Emanuela Salvatorelli	65
16	Modified Colistin Regimen for Critically Ill Patients with Acute Renal Impairment and Continuous Renal Replacement Therapy 2017 ·Chemotherapy ·Pierantonio Menna, Emanuela Salvatorelli, Alessia Mattei, (unknown), Giorgio Minotti, Massimiliano Carassiti	10
17	Doxorubicinolone Formation and Efflux: A Salvage Pathway against Epirubicin Accumulation in Human Heart 2009 ·Journal of Pharmacology and Experimental Therapeutics ·Emanuela Salvatorelli, Pierantonio Menna, Mario Lusini, Elvio Covino, Giorgio Minotti	20
18	Anthracycline Cardiotoxicity 2007 ·Topics in current chemistry ·Pierantonio Menna, Emanuela Salvatorelli, Luca Gianni, Giorgio Minotti	24
19	Anthracyclines: Molecular Advances and Pharmacologic Developments in Antitumor Activity and Cardiotoxicity breakdown → 2004 ·Pharmacological Reviews ·Giorgio Minotti, Pierantonio Menna, Emanuela Salvatorelli, Gaetano Cairo, Luca Gianni	3006
20	Oxidative Degradation of Cardiotoxic Anticancer Anthracyclines to Phthalic Acids 2004 ·Journal of Biological Chemistry ·Antonella Cartoni, Pierantonio Menna, Emanuela Salvatorelli, Daniela Braghiroli, (unknown), Fabio Animati, Andrea Urbani, Piero Del Boccio, Giorgio Minotti	29

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact